{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:50:15Z","timestamp":1768913415649,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ejim.2013.04.004","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T17:20:32Z","timestamp":1369070432000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients"],"prefix":"10.1016","volume":"24","author":[{"given":"Stefania","family":"Celeste","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Santaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Caronni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurij","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adirana","family":"Severino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.04.004_bb0005","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/ard.50.Suppl_4.854","article-title":"Clinical aspect of systemic sclerosis (scleroderma)","volume":"50","author":"Silver","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2013.04.004_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2013.04.004_bb0015","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/rheumatology\/kep109","article-title":"Pulmonary complications: one of the most challenging complications of systemic sclerosis","volume":"48","author":"Wells","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2013.04.004_bb0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2013.04.004_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2013.04.004_bb0030","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the scleroderma lung study placebo group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2013.04.004_bb0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1440-1843.2009.01600.x","article-title":"Non-invasive biomarkers in pulmonary fibrosis","volume":"14","author":"Prasse","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.ejim.2013.04.004_bb0040","first-page":"27","article-title":"Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement","volume":"28","author":"Bonella","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ejim.2013.04.004_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0050","first-page":"414","article-title":"Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato\/polymyositis","volume":"26","author":"Kum\u00e1novics","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0055","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/art.21257","article-title":"Serum pulmonary and activation-regulated chemokine\/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis","volume":"52","author":"Kodera","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2013.04.004_bb0060","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3899\/jrheum.100591","article-title":"Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis","volume":"38","author":"Hasegawa","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ijc.2910570717","article-title":"Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9","volume":"8","author":"Kohno","year":"1994","journal-title":"Int J Cancer Suppl"},{"key":"10.1016\/j.ejim.2013.04.004_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijc.2910570704","article-title":"Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis","volume":"8","author":"Stahel","year":"1994","journal-title":"Int J Cancer Suppl"},{"key":"10.1016\/j.ejim.2013.04.004_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10408360490452040","article-title":"MUC1 and the MUCs: a family of human mucins with impact in cancer biology","volume":"41","author":"Baldus","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ejim.2013.04.004_bb0080","first-page":"138","article-title":"CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases","volume":"27","author":"Kruit","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ejim.2013.04.004_bb0085","first-page":"54","article-title":"Serum CA 15-3 is increased in pulmonary fibrosis","volume":"26","author":"Ricci","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ejim.2013.04.004_bb0090","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1378\/chest.11-0284","article-title":"The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation","volume":"141","author":"Rusanov","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2013.04.004_bb0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archderm.134.5.645","article-title":"Elevated circulating CA 15.3 levels in a subset of systemic sclerosis with severe lung involvement","volume":"134","author":"Marzano","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2013.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s003300101003","article-title":"Ultrasound of the pancreas: update and controversies","volume":"11","author":"Mart\u00ednez-Noguera","year":"2001","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2013.04.004_bb0115","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subset and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/art.10561","article-title":"American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing","volume":"47","author":"Solomon","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2013.04.004_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"An index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2013.04.004_bb0130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/aje\/kwj063","article-title":"The inconsistency of \u201coptimal\u201d cutpoints obtained using two criteria based on the receiver operating characteristic curve","volume":"163","author":"Perkins","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.ejim.2013.04.004_bb0140","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/bimj.200610301","article-title":"Consistent estimation of the expected brier score in general survival models with right-censored event times","volume":"48","author":"Gerds","year":"2006","journal-title":"Biom J"},{"key":"10.1016\/j.ejim.2013.04.004_bb0145","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/sim.1486","article-title":"Predictive accuracy and explained variation","volume":"22","author":"Schemper","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.ejim.2013.04.004_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2353\/ajpath.2009.081170","article-title":"Emerging concepts in the pathogenesis of lung fibrosis","volume":"175","author":"Hardie","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejim.2013.04.004_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir Investig."},{"key":"10.1016\/j.ejim.2013.04.004_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2013.04.004_bb0165","first-page":"220","article-title":"Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers","volume":"3","author":"Inagaki","year":"2009","journal-title":"Biosci Trends"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513001076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T22:59:25Z","timestamp":1539644365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0953620513001076"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.04.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2013.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}